• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected

BACKGROUND: In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of the mark53 status for predicting the effect of two different neoadjuvant chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kappel-Latif, Sonja, Zacherl, Johannes, Hejna, Michael, Westerhoff, Maria, Tamandl, Dietmar, Ba-Ssalamah, Ahmed, Mittlböck, Martina, Wolf, Brigitte, Wrba, Friedrich, Kührer, Irene, Pluschnig, Ursula, Schoppmann, Sebastian F., Függer, Reinhold, Zwrtek, Ronald, Glaser, Karl, Karner, Josef, Längle, Friedrich, Wenzl, Etienne, Roka, Rudolf, Öfner, Dietmar, Tschmelitsch, Jörg, Hold, Michael, Keil, Felix, Gnant, Michael, Kandioler, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290852/
https://www.ncbi.nlm.nih.gov/pubmed/30559831
http://dx.doi.org/10.1007/s10353-018-0527-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290852/
https://www.ncbi.nlm.nih.gov/pubmed/30559831
http://dx.doi.org/10.1007/s10353-018-0527-z

Ejemplares similares